Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model

Vascular

Volumn 7, Issue 2, 1999, Pages 187-194

  Sakai, M ^a   Ohteki, H ^b   Narita, Y ^b   Naitoh, K ^a   Natsuaki, M ^a   Itoh, T ^a  

^a SAGA UNIVERSITY   (Japan)

^b Saga Prefectural Hospital KOSEIKAN 1 12 9 Mizugae   (Japan)

Author keywords

argatroban; cardiopulmonary bypass; thrombin inhibitor

Indexed keywords

ARGATROBAN; HEPARIN; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYSIS; INFUSION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; DOGS; FIBRINOLYSIS; HEMATOCRIT; HEPARIN; PIPECOLIC ACIDS; PLATELET COUNT;

EID: 0032927439     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721099900700208     Document Type: Article

References (20)

1. Ovrum E., Holen E. A., Tangen G., et al, Complete heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects. Annals of Thoracic Surgery, 1995, 60, 355–371.
2. Videm V., Mollnes T. E., Garre P., et al, Biocompatibility of extracorporeal circulation: in vitro comparison of heparin-coated and uncoated oxygenator circuits. Journal of Thoracic and Cardiovascular Surgery, 1991, 101, 654–660.
3. Gu Y. G., Van Oevern W., Akkernman C., et al, Heparincoated circuits reduce the inflammatory response to cardiopulmonary bypass. Annals of Thoracic Surgery, 1993, 55, 917–922.
4. Khuri S. F., Valeri C. R., Loscalzo J., et al, Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Annals of Thoracic Surgery, 1995, 60, 1008–1014.
5. McKenzie F. N., Dhall D. P., Arfors K. E., et al, Blood platelet behaviour during and after open-heart surgery. British Medical Journal, 1969, 2, 795–798.
6. Matsuo T., Nakao K., Yamada T., et al, Effect of a new anticoagulant (MD805) on platelet activation in the hemodialytic circuit. Thrombosis Research, 1986, 41, 33–41.
7. Usui A., Hiroura M., Kawamura M., et al, Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials. Annals of Thoracic Surgery, 1996, 62, 1404–1411.
8. Harker L. A., Malpass T. W., Bronson H. E., et al, Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective-granule release. Blood, 1980, 56, 824–834.
9. Kukuk O., Kwaan H. C., Frederickson J., et al, Increased fibrinolysis in patients undergoing cardiopulmonary bypass operations. American Journal of Hematology, 1986, 23, 223–229.
10. Tice D. A., Reed G. E., Clauss R. H., et al, Hemorrhage due to fibrinolysis occurring with open heart surgery. Journal of Thoracic and Cardiovascular Surgery, 1963, 46, 673–679.
11. Musial J., Niewiarowski S., Hershock D., et al, Loss of fibrinogen receptors from the platelet surface during stimulated extracorporeal circulation. Journal of Laboratory Clinical Medicine, 1985, 105, 514–522.
12. Okamoto S., Hijikata A., Kikumoto R., et al, Potent inhibition of thrombin by the newly synthesized arginine derivative No.805: The importance of stereostructure of its hydrophobic carboxamide portion. Biochemical Research Communications, 1981, 101, 440–446.
13. Kikumoto R., Tamao Y., Tezuka T., et al, Selective inhibition of thrombin by (2R,4R)-4-methyl-1-{N-(3-methyl-1,2,3,4 tetrahydro-8-quinolinesulfonyl)-L-arginyl}-2-piperidine carboxylic acid). Biochemistry, 1984, 23, 85–90.
14. Herrman J. P., Suryapanata H., Heijer P., et al, Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. Journal of Thrombosis and Thrombolysis, 1996, 3, 367–375.
15. Kawai H., Tamao Y., The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding. Thrombosis Research, 1995, 80, 429–434.
16. Matsuo T., Ohoki Y., Yamada T., et al, Comparison between a new anticoagulant (MD 805) and heparin on platelet release proteins (PF4,BTG) in patients with hemodialysis. Blood and Vessel, 1986, 17, 62–64.
17. Matso T., Kario K., Matsuda S., et al, Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban. Journal of Thrombosis and Thrombolysis, 1995, 2, 131–136.
18. Berry C. N., Girardot C., Lecoffre C., et al, Effect of the synthetic thrombin inhibitor of argatroban on fibrin-clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thrombosis and Haemostasis, 1994, 3, 381–386.
19. Sakai M., Ohteki H., Doi K., et al, Assessment of platelet function and coagulofibrinolytic activity with argatroban following cardiac surgery. Journal of the Japanese College of Angiology, 1996, 39, 15–20.
20. Kawada T., Mieda T., Hosono M., et al, Left heart bypass with the Bio-Medicus centrifugal pump: The use of argatroban for preventing platelet loss. Artificial Organs, 1992, 2, 177–184.